DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: 6,099,863
|Title:||Fast-dissolving galanthamine hydrobromide tablet|
|Abstract:||The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.|
|Inventor(s):||Gilis; Paul Marie Victor (Beerse, BE), De Conde; Valentin Florent Victor (Lommel, BE)|
|Assignee:||Janssen Pharmaceutica N.V. (Beerse, BE)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 6,099,863|
1. A tablet comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, wherein said
carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and an insoluble or poorly soluble cross-linked polymer disintegrant.
2. A tablet according to claim 1 wherein the disintegrant is crospolyvidone or croscarmellose.
3. A tablet according to claim 1 wherein the carrier further comprises a glidant and a lubricant.
4. A tablet according to claim 3 wherein the glidant is colloidal anhydrous silica and wherein the lubricant is magnesium stearate.
5. A tablet according to claim 1 comprising by weight based on the total weight:
(a) from 2 to 10% galanthamine hydrobromide (1:1);
(b) from 83 to 93% spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25);
(c) from 0.1 to 0.4% glidant;
(d) from 3 to 8% insoluble crosslinked polymeric disintegrant; and
(e) from 0.2 to 1% lubricant.
6. A tablet according to claim 5 comprising
(a) about 2 to 10% galanthamine hydrobromide (1:1);
(b) about 83 to 93% spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25);
(c) about 0.2% colloidal anhydrous silica;
(d) about 5% crospolyvidone; and
(e) about 0.5% magnesium stearate.
7. A tablet according to claim 1 which is film-coated.
8. A tablet according to claim 7 wherein the film-coat comprises a film-forming polymer and a plasticizer.
9. A tablet according to claim 8 wherein the film-coat weighs from about 3% to about 8% of the uncoated tablet core.
10. A process of preparing a tablet according to claim 3 comprising the steps of:
(i) dry blending the active ingredient, the disintegrant and the optional glidant with the diluent;
(ii) optionally mixing the lubricant with the mixture obtained in step (i);
(iii) compressing the mixture obtained in step (i) or in step (ii) in the dry state into a tablet; and
(iv) optionally film-coating the tablet obtained in step (iii).
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.